The 12 most common product-led growth mistakes and how to fix them for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install product-led growth has to reflect that reality from day one.

Every product-led growth failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.

Mistake one, the foundational one: bolting PLG onto a product that requires a demo to understand. Fix by naming an owner and writing kill criteria before you spend a dollar.

Mistake two: mistaking volume for progress. Fix by making self-serve activation to paid conversion the only weekly headline number.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Product-led growth is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.

Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.

Mistake five: ignoring the trigger. Product-led growth works when CAC collapses when the product qualifies for you; without a real trigger the model is guesswork.

Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing product-led growth properly rather than half-heartedly across three vendors.